Searchable abstracts of presentations at key conferences in endocrinology

ea0038p407 | Steroids | SFEBES2015

Conventional vs modified release hydrocortisone in mitotane treated patients with adrenocortical cancer

Weigel Marianne , Hahner Stefanie , Beier Daniela , Zopf Kathrin , Quinkler Marcus

Background: Mitotane is a strong inducer of hepatic CYP3A4 activity (cortisol metabolism) and increases cortisol-binding globulin (CBG). High hydrocortisone dosages are necessary in patients with adrenocortical cancer (ACC) on mitotane treatment. The newly modified release hydrocortisone has not been used in mitotane-treated ACC patients yet.Aim: To compare cortisol (serum and saliva), calculated free serum cortisol and ACTH levels in ACC patients on mit...

ea0026p20 | Adrenal cortex | ECE2011

Clinical presentation of Cushing’s syndrome in a large series from the European Registry on Cushing's syndrome (ERCUSYN)

Valassi Elena , Santos Alicia , Yaneva Maria , Toth Miklos , Strasburger Christian , Chanson Phillippe , Wass John , Chabre Olivier , Pfeifer Marija , Feelders Richard , Tsagarakis Stylianos , Trainer Peter , Franz Holger , Zopf Kathrin , Zacharieva Sabina , Lamberts Steven , Webb Susan

The European Registry on Cushing’s syndrome (ERCUSYN) is designed to collect prospective and follow-up data at EU level on patients with Cushing’s syndrome (CS). Baseline data on 481 CS patients (390 females, 91 males; mean age (±S.D.): 44±14 years) collected from 36 centres in 23 countries. This cohort included new patients since 2008 and retrospective cases since 2005. Patients were divided into four major etiologic groups: pituitary-depend...

ea0063p1107 | Pituitary and Neuroendocrinology 3 | ECE2019

European observational study of ketoconazole for endogenous cushing’s syndrome in collaboration with European registry on cushing’s syndrome ERCUSYN: PASS ketoconazole study design and rationale

Bostnavaron Martine , Marsault Pauline , Arosio Maura , Bertherat Jerome , Brue Thierry , Chabre Olivier , Chanson Philippe , Duarte Joao Sequeira , Fajardo Carmen , Feelders Richard , Alexandra Hanzu Felicia , Kastelan Darko , Netea-Maier Romana , Newell-Price John , Pereira Alberto , Ragnarsson Oskar , Reincke Martin , Strasburger Christian , Tabarin Antoine , Touraine Philippe , Trainer Peter , Pal Aparna , Zopf Kathrin , Franz Holger , Stalla Gunter , Santos Alicia , Valassi Elena , Werner Sandy , Webb Susan

Introduction and rationale: Cushing’s syndrome (CS) is a rare disease with hypercortisolism caused either by ACTH excess from a pituitary or non-pituitary tumor or by an ACTH-independent primary adrenal overproduction of cortisol. It is associated with significant comorbidities potentially lethal: hypertension, diabetes, coagulopathy, cardiovascular disease, infections, and osteoporotic fractures. It is usually managed by surgery and/or medical treatment with steroidogene...

ea0035oc5.1 | Adrenal & Thyroid | ECE2014

Diagnostic and therapeutic outcome in ERCUSYN: Preliminary report in over 1000 patients

Valassi Elena , Santos Alicia , Brue Thierry , Netea-Maier Romana T. , Feelders Richard A. , Yaneva Maria , Tsagarakis Stylianos , Pfeifer Marija , Chanson Philippe , Chabre Olivier , Zopf Kathrin , Toke Judit , Wass John AH , Droste Michael , Maiter Dominique , Dusek Tina , Komerdus Irina , Franz Holger , Lamberts Steven W.J. , Strasburger Christian J.

The European Registry on Cushing’s Syndrome (ERCUSYN) is designed to collect prospective and follow-up data on patients with Cushing’s syndrome (CS) and currently (Sep 2013) includes 1006 patients (804 F, 202 M; mean age (+S.D.) 44.7±13.3 years) from 57 centers in 28 countries.Six hundred and sixty one (66%) had pituitary-dependent CS (PIT-CS), 242 (24%) adrenal-dependent CS (ADR-CS), and 103 (10%) CS from other etiologies, ...